Last reviewed · How we verify
VIGIV
At a glance
| Generic name | VIGIV |
|---|---|
| Also known as | Vaccinia Immune Globulin Intravenous (Human) |
| Sponsor | Emergent BioSolutions |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
- VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV (PHASE3)
- VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIGIV CI brief — competitive landscape report
- VIGIV updates RSS · CI watch RSS
- Emergent BioSolutions portfolio CI